Clinical Impact of New HIV Data From EACS 2021*

In combined analysis of open-label extension, maintenance of virologic suppression was demonstrated through 192 weeks.

Across phase III/IIIb trials through Week 48, LA CAB + RPV maintained high rates of virologic suppression across dosing strategies and BMI categories; no participant with BMI ≥30 kg/m² as only baseline risk factor met CVF criterion.

Renal safety of daily TDF/FTC for PrEP acceptable, with few serious renal adverse events and none leading to permanent treatment discontinuation.

Maraviroc ± metformin, in addition to ART, was safe with acceptable tolerability but did not reduce liver fat percentage vs no adjunctive treatment.

Through 26 weeks, viral rebound on lenacapavir plus optimized background was associated with a lack of additional active ARVs resulting in functional LEN monotherapy.

In the phase IIb trial, continued high rates of efficacy were seen in the combined ISL plus DOR arm at 144 Weeks; no participants in this arm met criteria for resistance testing.

In open-label study, 2-drug regimen was found to be safe and effective at maintaining virologic suppression in patients with multiple previous virologic failures and historic or current M184V/I.

Change in serum IL-6 levels from baseline to Week 96 were similar between patients with virologic suppression who switched to DTG/3TC and those who continued TAF-based ART.

Participants found LA CAB + RPV to be an acceptable, appropriate, and feasible treatment option for maintenance of HIV virologic suppression from Months 1 to 4.

In this small test-and-treat study, regimen was more than 80% effective at suppressing HIV-1 RNA at Week 24 with no treatment-emergent resistance seen in patients who did not achieve viral suppression; very low incidence of grade 3/4 or serious adverse events was seen.